|Day Low/High||84.67 / 89.40|
|52 Wk Low/High||78.95 / 116.49|
Quest Diagnostics -- and others in this beaten-down sector -- are excellent trading vehicles.
Bio-Reference Labs CEO Dr. Marc Grodman says the Supreme Court ruling against human gene patents means big things for the testing industry.
It's much tougher to actually "buy low to sell high" than it is to espouse the concept.
The fear of 'dead money' has brought Quest back to an extremely low-risk entry point.
I execute a dividend-rotation strategy, trading in and out of stocks to capture the dividend payment. Those of you who also read the Real Money site know me as the "Dividend Diva." In one of my partnerships, I execute a dividend-rotation strategy, t...
Names tied to the cosmetic medical market will be vulnerable until consumer sentiment and disposable income rebound.
This is a speculative trade, and preserving capital is job one.
Volatility has retraced, but will remain with earnings reports coming fast and furious this week.